The paper's citation list
No. | The paper's citation list |
|---|
1 | Immune Signatures Identify Patient Subsets Deriving Long‐Term Benefit From First‐Line Rituximab in Follicular Lymphoma. 2025;6: doi: 10.1002/jha2.1103 |
Your privacy, your choice
We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.
By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our privacy policy for more information on the use of your personal data.
